Trial Profile
A Phase I Open-label Dose Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 2536 (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 11 Aug 2014 Planned number of patients changed from 41 to NULL.
- 11 Aug 2014 New trial record